AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24711542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir monotherapy for one week
Number of subjects: 32
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir/pegylated interferon-alpha-2b combination therapy for two weeks
Number of subjects: 32
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir retreatment
Number of subjects: 32
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir dosing
Number of subjects: 32
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir treatment
Number of subjects: 32
Study 24168257 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up
Number of subjects: 32
Study 21172584 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (DUS) imaging
Number of subjects: 992
Study 21172584 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT) imaging
Number of subjects: 992
Study 21172584 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary interventions
Number of subjects: 992
Study 19709109 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss (control group)
Number of subjects: 14
Study 19709109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss and Bio‐Gide (test group)
Number of subjects: 14
Study 17381934 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed school meals
Number of subjects: 120
Study 17381934 — intervention group
Group type: COMPARATOR
Intervention: Not observed school meals
Number of subjects: 120
Study 17381934 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior 24 hours interviews
Number of subjects: 120
Study 17381934 — intervention group
Group type: COMPARATOR
Intervention: Previous day interviews
Number of subjects: 120
Study 15005645 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg Phase 2 twice daily with meals
Number of subjects: 50
Study 15005645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11588409 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat combined with hydrochlorothiazide
Number of subjects: 274
Study 11588409 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 274
Study 9632325 — intervention group
Group type: EXPERIMENTAL
Intervention: Music walk
Number of subjects: 19
Study 9632325 — intervention group
Group type: COMPARATOR
Intervention: Control walk
Number of subjects: 19
Study 8872666 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred limb (tennis playing arm)
Number of subjects: 8
Study 8872666 — intervention group
Group type: COMPARATOR
Intervention: Nonpreferred limb (non-tennis playing arm)
Number of subjects: 8
Study 8872666 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine infusion
Number of subjects: 8
Study 8872666 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside infusion
Number of subjects: 8
Study 8872666 — intervention group
Group type: COMPARATOR
Intervention: NG-mononmethyl-L-arginine infusion
Number of subjects: 8
Study 2574084 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) infusion (4 micrograms/min)
Number of subjects: 6
Study 2574084 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 6
Study 2574084 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SMS) infusion
Number of subjects: 6
Study 1097203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (5 mg)
Number of subjects: 20
Study 1097203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ephedrine (25 mg)
Number of subjects: 20
Study 1097203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31730370 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented treatment (titrated risperidone)
Number of subjects: 0
Study 31730370 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (placebo)
Number of subjects: 0
Study 31533093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-salt diet education
Number of subjects: 171
Study 31533093 — intervention group
Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 171
Study 28805135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (initially continuous dosing)
Number of subjects: 2
Study 28805135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedule (five‐week‐on and three‐week‐off)
Number of subjects: 2
Study 28805135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dosing schedule
Number of subjects: 2
Study 25668654 — intervention group
Group type: EXPERIMENTAL
Intervention: High life satisfaction in individuals with schizophrenia
Number of subjects: 0
Study 25668654 — intervention group
Group type: COMPARATOR
Intervention: Moderate-severe symptoms and severe functional deficits
Number of subjects: 0
Study 23443947 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with Tc-99m
Number of subjects: 140
Study 23443947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate with Tc-99m
Number of subjects: 140
Study 23443947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-lidocaine with Tc-99m
Number of subjects: 140
Study 23443947 — intervention group
Group type: COMPARATOR
Intervention: Control (4% lidocaine cream and Tc-99m)
Number of subjects: 140
Study 20953872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoidectomy
Number of subjects: 149
Study 20953872 — intervention group
Group type: COMPARATOR
Intervention: Open sigmoidectomy
Number of subjects: 149
Study 19906343 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI
Number of subjects: 37
Study 19906343 — intervention group
Group type: COMPARATOR
Intervention: ORAL
Number of subjects: 37
Study 16972829 — intervention group
Group type: EXPERIMENTAL
Intervention: hand-held video game (VG)
Number of subjects: 112
Study 16972829 — intervention group
Group type: COMPARATOR
Intervention: parent presence (PP)
Number of subjects: 112
Study 16972829 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg.kg‐1 oral midazolam (M)
Number of subjects: 112
Study 15179204 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver with vibration
Number of subjects: 102
Study 15179204 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning maneuver without vibration
Number of subjects: 102
Study 11419228 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers who quit smoking by 28 weeks of pregnancy (n = 102)
Number of subjects: 897
Study 11419228 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 897
Study 11419228 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of intrinsic motivation at baseline
Number of subjects: 897
Study 9247476 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU IFN three times a week for 6 months
Number of subjects: 272
Study 9247476 — intervention group
Group type: COMPARATOR
Intervention: 6 MU IFN three times a week for 6 months
Number of subjects: 272
Study 9247476 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Number of subjects: 272
Study 9247476 — intervention group
Group type: COMPARATOR
Intervention: 6 MU IFN in patients with intermediate virus load (10(4)‐10(5) copies/mL)
Number of subjects: 272
Study 9247476 — intervention group
Group type: COMPARATOR
Intervention: 6 MU IFN
Number of subjects: 272
Study 9247476 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 MU IFN
Number of subjects: 272
Study 8495279 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 55
Study 8495279 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 55
Study 3651531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 19
Study 3651531 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 19
Study 3651531 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose infusion
Number of subjects: 19
Study 3651531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate and Isoproterenol infusions
Number of subjects: 19
Study 31038440 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ballet classes
Number of subjects: 19
Study 31038440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dance classes)
Number of subjects: 19
Study 28544009 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief personality-targeted interventions delivered to high-risk youth during the first year of the trial.
Number of subjects: 3826
Study 28544009 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no intervention above regular curriculum.
Number of subjects: 3826
Study 26468478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour tea pill (500 mg)
Number of subjects: 20
Study 26468478 — intervention group
Group type: COMPARATOR
Intervention: Captopril (12.5 mg twice daily)
Number of subjects: 20
Study 24464572 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholized group (0.06% BAC)
Number of subjects: 20
Study 24464572 — intervention group
Group type: COMPARATOR
Intervention: Control group (sober)
Number of subjects: 20
Study 24464572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (learning effect observed)
Number of subjects: 20
Study 21242557 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support
Number of subjects: 5234
Study 21242557 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5234
Study 21242557 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support for patients on low-dose aspirin
Number of subjects: 5234
Study 21242557 — intervention group
Group type: COMPARATOR
Intervention: Usual care for patients on low-dose aspirin
Number of subjects: 5234
Study 19101042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral choanal atresia patients
Number of subjects: 9
Study 19101042 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 9
Study 16922930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunization with E-GTF (n = 7)
Number of subjects: 26
Study 16922930 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 12)
Number of subjects: 26
Study 16922930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillar immunization (IT, n = 7)
Number of subjects: 26
Study 12893996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and imagery delivered on two evenings
Number of subjects: 36
Study 10630436 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate formula
Number of subjects: 6
Study 10630436 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk‐based formula
Number of subjects: 6
Study 9375877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose amitriptyline (up to 30 mg nightly)
Number of subjects: 100
Study 9375877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8269183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 g/d for 3 weeks)
Number of subjects: 15
Study 8269183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (after olive oil)
Number of subjects: 15
Study 8269183 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (12 g/d for 3 weeks)
Number of subjects: 15
Study 8269183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 15
Study 8269183 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 15
Study 2994988 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 20 mg twice‐daily) and Hydrochlorothiazide (50 to 100 mg/day)
Number of subjects: 18
Study 2994988 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy (Hydrochlorothiazide (50 to 100 mg/day), Timolol (10 to 30 mg twice‐daily), Hydralazine (50 to 150 mg twice‐daily)
Number of subjects: 18
Study 31989291 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 120
Study 31989291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-pack application
Number of subjects: 120
Study 31989291 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 120
Study 29493328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration of the lateral cutaneous femoral and subcostal nerve
Number of subjects: 162
Study 29493328 — intervention group
Group type: COMPARATOR
Intervention: Placebo infiltration
Number of subjects: 162
Study 29493328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration
Number of subjects: 162
Study 27603903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX) 4 mg/kg/d for 6 months
Number of subjects: 35
Study 27603903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27603903 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX)
Number of subjects: 35
Study 24262433 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mmHg
Number of subjects: 234
Study 24262433 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mmHg
Number of subjects: 234
Study 24262433 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mmHg
Number of subjects: 234
Study 24262433 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain scores
Number of subjects: 234
Study 21835081 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component programme delivered in school by teachers and items sent home for parents/children
Number of subjects: 311
Study 21835081 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating main meal with parents 3-7 nights/week
Number of subjects: 311
Study 21835081 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 311
Study 20171357 — intervention group
Group type: EXPERIMENTAL
Intervention: IAN block administered with a peripheral nerve stimulator
Number of subjects: 46
Study 20171357 — intervention group
Group type: COMPARATOR
Intervention: Conventional IAN block with 2% lidocaine and 1:100,000 epinephrine
Number of subjects: 46
Study 18598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and hydrocortisone (CHC) 3 drops twice daily for 7 days
Number of subjects: 206
Study 18598837 — intervention group
Group type: COMPARATOR
Intervention: NPH + AMX (neomycin/polymyxin b/hydrocortisone with systemic amoxicillin)
Number of subjects: 206
Study 18598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and hydrocortisone (CHC)
Number of subjects: 206
Study 15830198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri. Twin MIOL
Number of subjects: 30
Study 15830198 — intervention group
Group type: COMPARATOR
Intervention: Array SA40 MIOL
Number of subjects: 30
Study 15830198 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MIOL
Number of subjects: 30
Study 11940133 — intervention group
Group type: EXPERIMENTAL
Intervention: Zelen design intervention group
Number of subjects: 0
Study 11940133 — intervention group
Group type: COMPARATOR
Intervention: Conventional randomized controlled trial
Number of subjects: 0
Study 10355618 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary liquid dentifrice
Number of subjects: 0
Study 10355618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 0
Study 10355618 — intervention group
Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 0
Study 8530574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (NAF; 400 micrograms, intranasal spray, twice daily)
Number of subjects: 64
Study 8530574 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone (NOR 1/35; 0.035 mg, daily, for 3 of 4 weeks)
Number of subjects: 64
Study 8530574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nafarelin and Norethindrone
Number of subjects: 64
Study 8530574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 1742820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 60
Study 1742820 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (200 micrograms)
Number of subjects: 60
Study 7037351 — intervention group
Group type: EXPERIMENTAL
Intervention: Optisulin ‐depot CS (25% dissolved porcine Des‐Phe‐insulin/insulin and 75% crystalline porcine insulin)
Number of subjects: 20
Study 7037351 — intervention group
Group type: COMPARATOR
Intervention: Depot Insulin Hoechst CS
Number of subjects: 20
Study 7037351 — intervention group
Group type: COMPARATOR
Intervention: Insulin Leo Mixtard
Number of subjects: 20
Study 31285653 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's 4-step approach
Number of subjects: 16
Study 31285653 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 16
Study 27372380 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8mg)
Number of subjects: 81
Study 27372380 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (8mg)
Number of subjects: 81
Study 27372380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 27372380 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Number of subjects: 81
Study 25925484 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 0
Study 24926544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 92
Study 24926544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23049590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) treatment for 6 weeks
Number of subjects: 148
Study 23049590 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (guideline‐based management)
Number of subjects: 148
Study 19032569 — intervention group
Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 180
Study 19032569 — intervention group
Group type: COMPARATOR
Intervention: Audio calls
Number of subjects: 180
Study 18182872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand acupuncture therapy using New Seoam Press Pellets number 1 for 4 weeks
Number of subjects: 22
Study 18182872 — intervention group
Group type: COMPARATOR
Intervention: Sham group using Adhesive tape for 4 weeks
Number of subjects: 22
Study 18182872 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood flow test
Number of subjects: 22
Study 16089103 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-radiotherapy (cisplatin + etoposide + early concurrent thoracic radiotherapy)
Number of subjects: 72
Study 16089103 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin + etoposide)
Number of subjects: 72
Study 11923793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercessory Prayer (IP) for 14 consecutive days starting the night before surgery
Number of subjects: 1802
Study 11923793 — intervention group
Group type: COMPARATOR
Intervention: No Intercessory Prayer (IP)
Number of subjects: 1802
Study 11923793 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed they would receive additional IP and did so
Number of subjects: 1802
Study 10617169 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg)
Number of subjects: 8
Study 10617169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8606523 — intervention group
Group type: COMPARATOR
Intervention: 80 mg propranolol
Number of subjects: 12
Study 8606523 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg talinolol
Number of subjects: 12
Study 8606523 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg talinolol
Number of subjects: 12
Study 8606523 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg talinolol
Number of subjects: 12
Study 8606523 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg talinolol
Number of subjects: 12
Study 8606523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2291875 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifoxamine 100 mg by i.v. infusion over 15 min
Number of subjects: 12
Study 2291875 — intervention group
Group type: EXPERIMENTAL
Intervention: Medifoxamine 500 mg by mouth fasting
Number of subjects: 12
Study 2291875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Medifoxamine
Number of subjects: 12
Study 7396472 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of probenecid administered concomitantly with 2 g of cefoxitin intravenously
Number of subjects: 12
Study 7396472 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of probenecid administered 1 hour prior to 2 g of cefoxitin intravenously
Number of subjects: 12
Study 7396472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of probenecid administered with 2 g of cefoxitin intramuscularly
Number of subjects: 12
Study 7396472 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of probenecid administered before 2 g of cefoxitin intravenously
Number of subjects: 12
Study 31478939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-thoracoscopy
Number of subjects: 73
Study 31478939 — intervention group
Group type: COMPARATOR
Intervention: Semirigid thoracoscopy
Number of subjects: 73
Study 31757089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration feedback
Number of subjects: 26
Study 31757089 — intervention group
Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 26
Study 28922999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive auditory‐visuospatial dual n‐back training task
Number of subjects: 0
Study 28922999 — intervention group
Group type: COMPARATOR
Intervention: Active or Passive WM composites
Number of subjects: 0
Study 25830402 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted cemented restorations
Number of subjects: 44
Study 25830402 — intervention group
Group type: COMPARATOR
Intervention: Nonsplinted cemented restorations
Number of subjects: 44
Study 23314231 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold argon laser therapy
Number of subjects: 37
Study 23314231 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 37
Study 21784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from laser head to skin at 10 cm
Number of subjects: 11
Study 21784084 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance from laser head to skin at 15 cm
Number of subjects: 11